Human papillomavirus vaccination in the UK

doi:10.1136/bmj.a842

Published 17 July 2008, doi:10.1136/bmj.a842
Cite this as: BMJ 2008;337:a842

Editorials

Human papillomavirus vaccination in the UK

Is projected to be beneficial and cost effective

The first 150 words of the full text of this article appear below.

This September, the Department of Health in the United Kingdomwill begin a national programme of routine human papillomavirusimmunisation of 12-13 year old schoolgirls, coupled with a twoyear catch-up campaign for those up to the age of 18 in 2009.¹The selected bivalent vaccine, Cervarix, protects against twoof the most common human papillomavirus types that cause cervicalcancer (types 16 and 18), whereas an available quadrivalentvaccine, Gardasil, also protects against two non-oncogenic typesthat cause genital warts (types 6 and 11). The linked studyby Jit and colleagues from the Health Protection Agency (doi:10.1136/bmj.a769) describes the mathematical modelling approachand results used to inform the Department of Health’sdecision.²

Mathematical models are used to synthesise multiple data sources,to extrapolate short term clinical findings into long term outcomesof population level benefits and cost effectiveness, and toinvestigate the influence of uncertainties about data . . . [Full text of this article]

Jane J Kim, assistant professor of health decision science

¹ Program in Health Decision Science, Department of Health Policy and Management, Harvard School of Public Health, Boston, MA 02115, USA

jkim@hsph.harvard.edu

CiteULike

Complore

Connotea

Del.icio.us Add to Digg

Digg

StumbleUpon Add to Technorati

Technorati What's this?

Relevant Articles

Economic evaluation of human papillomavirus vaccination in the United Kingdom: Mark Jit, Yoon Hong Choi, and W John Edmunds
BMJ 2008 337: a769. [Abstract] [Full Text] [PDF]

Uptake of first two doses of human papillomavirus vaccine by adolescent schoolgirls in Manchester: prospective cohort study: Loretta Brabin, Stephen A Roberts, Rebecca Stretch, David Baxter, Gloria Chambers, Henry Kitchener, and Rosemary McCann
BMJ 2008 336: 1056-1058. [Abstract] [Full Text] [PDF]

Rapid Responses:

Read all Rapid Responses

How efficient are these vaccines really?: Ian N Miskin
bmj.com, 23 Jul 2008 [Full text]
Dilemmas with HPV vaccination programme: Tom J. Black
bmj.com, 12 Aug 2008 [Full text]
A lost opportunity in HPV immunisation: Peter D Bull
bmj.com, 13 Aug 2008 [Full text]
HPV infection is more than Cervical Cancer and Genital Warts.: Desmond A Nunez
bmj.com, 13 Aug 2008 [Full text]
The choice of vaccine and exclusion of MSMs: Ravindra Gokhale
bmj.com, 13 Aug 2008 [Full text]